The size of the MEA Parkinson’s Disease Treatment Market was worth USD 0.46 billion in 2021 and estimated to be growing at a CAGR of 4.807%, to reach USD 0.58 billion by 2026.
Parkinson's disease is a long-term degenerative disorder of the central nervous system which chiefly affects the motor system. The symptoms usually come on slowly with time. In the earlier stages of the disease, the most obvious are rigidity, shaking, slowness of movement, and difficulty in walking. Thinking and behavioral problems may also occur. Dementia becomes common during the advanced stages of the disease. Anxiety and depression are also common occurrences in more than a third of people with this disease. Other symptoms include sleep, sensory, and emotional problems.
The cause of Parkinson's disease is usually unknown, but it is believed to involve both environmental and genetic factors. Those who have a family member affected are more likely to get the disease themselves. There is also a higher risk in people exposed to certain pesticides and among those who have had prior head injuries, while there is a reduced risk in tobacco smokers and those who drink tea or coffee. The motor symptoms of the disease result from the death of cells in the substantia nigra which is a region of the midbrain. This results in fewer amounts of dopamine in these areas. Diagnosis of typical cases is mainly based on symptoms, with tests such as neuroimaging which is used to rule out other diseases.
The driving factors of the Middle East and Africa Parkinson’s Disease Treatment market are growth in the aging population and the associated increase in the prevalence of Parkinson's disease and government funding for research. However, the market is constrained by factors such as the availability of alternative options for Parkinson’s disease management.
This research report on the Middle East & Africa Parkinson’s Disease Treatment Market has been segmented and sub-segmented into the following categories:
By Drug Class:
By Distribution Channels:
By Patient Care Setting:
By Country:
Based on the Drug Class, Carbidopa has the largest share in the segment.
Based on the Distribution Channel, the Hospital pharmacies have the largest share in the segment.
Based on the Patient Care Setting, the market is classified into clinics and hospitals. hospitals have the largest share in this segment. Factors such as the growing geriatric population and increasing government funding for research are expected to drive the region's market growth. The market in the region can be geographically segmented into the Middle East and Africa regions.
Notable companies playing a leading role in the MEA Parkinson’s Disease Treatment Market profiled in the report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Dopamine Receptor Antagonists
5.1.1.1 Pramipexole
5.1.1.2 Ropinirole
5.1.1.3 Apomorphine
5.1.1.4 Rotigotine
5.1.2 Mono Amine Oxidase Inhibitors
5.1.2.1 Selegiline
5.1.2.2 Rasagiline
5.1.3 Carbidopa
5.1.4 Anticholinergics
5.1.5 Other Drug Classes
5.1.6 Y-o-Y Growth Analysis, By Drug Class
5.1.7 Market Attractiveness Analysis, By Drug Class
5.1.8 Market Share Analysis, By Drug Class
5.2 Distribution Channel
5.2.1 Retailer Pharmacies
5.2.2 Hospital Pharmacies
5.2.3 Online Pharmacies
5.2.4 Y-o-Y Growth Analysis, By Distribution Channel
5.2.5 Market Attractiveness Analysis, By Distribution Channel
5.2.6 Market Share Analysis, By Distribution Channel
5.3 Patient Care Setting
5.3.1 Clinics
5.3.2 Hospitals
5.3.3 Y-o-Y Growth Analysis, By Patient Care Setting
5.3.4 Market Attractiveness Analysis, By Patient Care Setting
5.3.5 Market Share Analysis, By Patient Care Setting
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Drug Class
6.1.3.2 By Distribution Channel
6.1.3.3 By Patient Care Setting
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Drug Class
6.1.4.2 By Distribution Channel
6.1.4.3 By Patient Care Setting
6.1.5 Market Share Analysis
6.1.5.1 By Drug Class
6.1.5.2 By Distribution Channel
6.1.5.3 By Patient Care Setting
6.2 Middle-East
6.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Teva
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis AG
8.3 GSK
8.4 AbbVie
8.5 Merck
8.6 Boehringer Ingelheim
8.7 Impax Laboratories
8.8 Lundbeck
8.9 Sun Pharma
8.10 Wockhardt
8.11 UCB
8.12 Valeant Pharmaceuticals
8.13 Acadia
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
